

Complete listing of claims:

1. (Currently amended) A method of improving the pharmacokinetic profile of administering ~~a drug for which the major clearance mechanism in humans is CYP2D6-mediated oxidative biotransformation and that is (2S,3S)-2-phenyl-3-(2-methoxy-5-trifluoromethoxyphenyl)methylamino-piperidine, or a pharmaceutically acceptable salt thereof, the method comprising administering (2S,3S)-2-phenyl-3-(2-methoxy-5-trifluoromethoxyphenyl)methylamino-piperidine, or the pharmaceutically acceptable salt thereof,~~ in combination with a CYP2D6 inhibitor, ~~or a pharmaceutically acceptable salt thereof, to a human in need of the intended pharmaceutical activity of such drug, wherein said drug and said CYP2D6 inhibitor are not the same compound~~ selected from the group consisting of quinidine, aimalacine and pharmaceutically acceptable salts thereof.

2-23. (cancelled)